The Rate of Re-treatment in Patients Treated with Teprotumumab
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Author:
Ugradar Shoaib,
Parunakian EmanuilORCID,
Malkhasyan Emil,
Chiou Carolina A.,
Walsh Hannah L.ORCID,
Tolentino Joseph,
Wester Sara T.,
Freitag Suzanne K.,
Douglas Raymond S.
Reference21 articles.
1. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association;Burch;Thyroid,2022
2. Teprotumumab for thyroid-associated ophthalmopathy;Smith;N Engl J Med,2017
3. Teprotumumab for the treatment of active thyroid eye disease;Douglas;N Engl J Med,2020
4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials;Kahaly;Lancet Diabetes Endocrinol,2021
5. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study;Douglas;Ophthalmology,2022